
1. antivir ther. 2007;12 suppl 3:h33-41.

treatment chronic hepatitis b.

loomba r(1), liang tj.

author information: 
(1)liver diseases branch, national institute diabetes digestive kidney
diseases, national institutes health, bethesda, ma, usa. roloomba@ucsd.edu

hepatitis b virus (hbv) infection leading cause chronic liver disease
and hepatocellular carcinoma worldwide. approximately 350 million individuals are
infected hbv >500,000 deaths per year attributed hbv. although
universal vaccination reduced hbv incidence many countries, still
remains major public health problem, especially parts asia africa.
improved understanding hbv virology virus-host interactions has
revolutionized chronic hepatitis b therapy past two decades. development
of oral nucleoside/nucleotide analogues heralds new era safe effective
treatment disease. basis advances, new guidelines the
treatment chronic hepatitis b issued. successful long-term treatment
of chronic hepatitis b may rest combination therapy based molecular
approaches targeting various stages hbv life-cycle. review, we
summarize current modalities highlight important issues treatment 
of chronic hepatitis b monoinfection.


pmid: 18284181  [indexed medline]

